Trials / Active Not Recruiting
Active Not RecruitingNCT05918042
A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation
Multicentre, Non-interventional, Observational, Prospective Study to Evaluate 1-st Line Treatment Approaches in HRD+ Ovarian Cancer Patients in Russian Federation
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study population will consist of HRD+ (BRCAm +/- positive genomic instability score according to used test system) OC with available medical history. It is estimated that approximately 400 patients will be enrolled in approximately 25 sites. Demographic and clinical characteristics, treatment approaches and outcomes in HRD+ patients with high-grade epithelial ovarian, primary peritoneal, and/or fallopian tube cancer will be collected at baseline and on prospective visits.
Conditions
Timeline
- Start date
- 2023-06-21
- Primary completion
- 2025-07-31
- Completion
- 2025-07-31
- First posted
- 2023-06-26
- Last updated
- 2025-07-03
Locations
24 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT05918042. Inclusion in this directory is not an endorsement.